Bradner James E. 4

What Happened
James E. Bradner, Executive Vice President, Research & Development at Amgen (AMGN), disposed of a total of 3,104 shares on Feb 9, 2026 to satisfy tax withholding related to vested restricted stock units (RSUs). The transactions were recorded as dispositions to cover tax liability (code F): 2,151 shares at $384.32 each ($826,672) and 953 shares at $384.32 each ($366,257), totaling $1,192,929.28 (~$1.19M). These were not open-market sales for portfolio reasons but share surrenders to cover withholding obligations.

Key Details

• Transaction date: February 9, 2026; Form 4 filed Feb 10, 2026 (timely filing).
• Prices and amounts: 2,151 shares @ $384.32 = $826,672; 953 shares @ $384.32 = $366,257; total = $1,192,929.28.
• Transaction code: F — payment of exercise price or tax liability (share disposition to cover taxes).
• Shares included: Filing notes these shares include 1,205 Dividend Equivalents (DEs) credited to unvested RSUs and paid out in shares per the plan.
• Shares owned after transaction: Not specified in the provided Form 4 data.
• No indication of a 10b5-1 plan or gift; this was routine withholding on vesting, not a directional purchase.

Context
This was a tax-withholding disposition tied to RSU vesting (including Dividend Equivalents). Such surrenders are common and typically administrative — they don’t necessarily indicate the insider’s market view. For retail investors, outright purchases by insiders tend to carry more weight as a bullish signal; routine withholding disposals are primarily procedural.